Codiak Biosciences Inc (CDAK) Return on Equity ROE from the third quarter 2022 to third quarter 2021 and annually, average high and low, overall ranking from Sep 30 2022 to Sep 30 2021 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Codiak Biosciences Inc   (NASDAQ: CDAK)

Codiak Biosciences Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Codiak Biosciences Inc in the third quarter 2022?
Codiak Biosciences Inc recorded a cumulative net loss of $-17 million during 12 months ending in the third quarter 2022, resulting in a negative return on equity (ROE) of -37.62%.

Within the Biotechnology & Pharmaceuticals industry 50 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2022 from 0 to 3428.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2022)
III. Quarter		 (Jun 30 2022)
II. Quarter		 (Mar 31 2022)
I. Quarter		 (Dec 31 2021)
IV. Quarter		 (Sep 30 2021)
III. Quarter
Y / Y Equity Change 14.48 % -14.4 % -29.6 % 267.3 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -17 -20 -35 -37 -72
Return On Equity (TTM) -37.62 % -44.03 % -74.3 % -71.42 % -169.73 %
CDAK's Total Ranking # 3428 # 0 # 0 # 0 # 0
Equity (TTM) in Millions 39 44 48 54 34
Seq. Equity Change -12.32 % -8.23 % -9.58 % 57.34 % -34.43 %
Seq. Net Income Change - - - - -

Back to CDAK Management Effectiveness >> CDAK's 5 Years Annual ROE >> Compare CDAK ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 51
Sector # 432
Overall # 3428

Return On Equity Statistics
High Average Low
-37.62 %
-79.42 %
-169.73 %
(Sep 30 2022)   (Sep 30 2021)





CDAK Annual Return On Equity (Dec 31 2021)
2021		 (Dec 31 2020)
2020


Total Equity in Millions 54 15 0 0 0
Y / Y Equity Change 267.3 % - - - -
Net Income in Millions -37 -92 0 0 0
Y / Y Net Income Change - - - - -
Return On Equity -69.45 % -629.26 % - - -

Back to CDAK Management Effectiveness >> CDAK's 5 Years Annual ROE >> Compare CDAK ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
CDAK's' Return on Equity at Yahoo Finance
CDAK's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for CDAK's Competitors
Subscribers only: Roe for Codiak Biosciences Inc 's Suppliers
Subscribers only: Return On Equity for CDAK's Customers




Companies with similar Return On Equity at Sep 30 2022, within Healthcare Sector ROE

Date modified: 2026-09-26T07:39:01+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.